BJE6-106 (B106)

Request For Quotation
BJE6-106 (B106) Suppliers list
Company Name: Sichuan Wei Keqi Biological Technology Co., Ltd.  
Tel: 028-81700200 18116577057
Email: 3003855609@qq.com
Company Name: Shanghai EFE Biological Technology Co., Ltd.  
Tel: 021-65675885 18964387627
Email: info@efebio.com
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 15026964105
Email: 2881489226@qq.com
Company Name: Fan De(Beijing) Biotechnology Co., Ltd.  
Tel: 15911056312
Email: liming@bio-fount.com
Company Name: BOC Sciences  
Tel: 16314854226; +8616314854226
Email: inquiry@bocsci.com

BJE6-106 (B106) manufacturers

  • BJE6-106
  • BJE6-106 pictures
  • 2026-07-14
  • CAS:1564249-38-2
  • Purity:
  • Supply Ability: 10g
BJE6-106 (B106) Basic information
Product Name:BJE6-106 (B106)
Synonyms:BJE6-106 (B106);B106;BJE6106,BJE-6-106,BJE6 106;2H-1-Benzopyran-8-carboxaldehyde, 6-[2-(9H-carbazol-9-yl)ethyl]-2,2-dimethyl-
CAS:1564249-38-2
MF:C26H23NO2
MW:381.47
EINECS:
Product Categories:
Mol File:1564249-38-2.mol
BJE6-106 (B106) Structure
BJE6-106 (B106) Chemical Properties
Boiling point 548.1±50.0 °C(Predicted)
density 1.16±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
solubility DMSO:50.0(Max Conc. mg/mL);131.07(Max Conc. mM)
form Solid
color White to off-white
Safety Information
MSDS Information
BJE6-106 (B106) Usage And Synthesis
UsesBJE6-106 (B106) is a potent, selective 3rd generation PKCδ inhibitor with an IC50 of 0.05 μM and targets selectivity over classical PKC isozyme PKCα (IC50=50 μM). BJE6-106 (B106) induces caspase-dependent apoptosis. BJE6-106 (B106) possesses tumor-specific effect.
Biological ActivityBJE6-106 (B106) is a potent and selective PKCδ inhibitor with IC50 value of 0.05 μM, BJE6-106 (B106) targets PKCδ 1000-fold more selective than the PKC isoenzyme PKCα (IC50=50 μM) . BJE6-106 (B106) induces apoptosis in caspase-dependent cells. BJE6-106 (B106) has tumor-specific effects.
in vitro

BJE6-106 (B106) (0.2 μM, 0.5 μM; 24-72 hours) suppresses cell survival in melanoma cell lines with NRAS mutations. BJE6-106 (B106) (0.2 μM, 0.5 μM; 6- 24 hours) triggers caspase-dependent apoptosis, increases the activity of caspase 3/7, the effect of B106 is greater than rottlerin (10-fold) in SBcl2 cells. BJE6-106 (B106) (0.5 μM; 2-10 hours) activates the MKK4-JNK-H2AX Pathway by inducing MKK4, JNK and H2AX activation at different times in SBcl2 cells.

Cell Viability Assay

Cell Line: Melanoma cell lines with NRAS mutations: SBcl2, FM6, SKMEL2, WM1366, WM1361A, and WM852 cells
Concentration: 0.2 μM, 0.5 μM
Incubation Time: 24 hours, 48 hours, or 72 hours
Result: Inhibited cell survival in melanoma cell lines.

Apoptosis Analysis

< td class="col2"> SBcl2 cells
Cell Line:
Concentration: 0.2 μM, 0.5 μM
Incubation Time: 6 hours, 12 hours, or 24 hours
Result: Induced caspase 3/7 activation.

Western Blot Analysis

< /tr> Result:
Cell Line : SBcl2 cells
Concentration: 0.2 μM , 0.5 μM
Incubation Time: 2 hours, 5 hours, 10 hours
Increased phosphorylation of MKK4, JNK and H2AX.
target

PKCδ

0.05 μM (IC 50 )

PKCα

50 μM (IC 50 )

IC 50PKCδ: 0.05 μM (IC50); PKCα: 50 μM (IC50)
References[1] Takashima A,et al. Protein kinase Cδ is a therapeutic target in malignant melanoma with NRAS mutation. ACS Chem Biol. 2014 Apr 18;9(4):1003-14. DOI:10.1021/cb400837t
BJE6-106 (B106) Preparation Products And Raw materials
Tag:BJE6-106 (B106)(1564249-38-2) Related Product Information
Anti-cancer compound library Apoptosis Compound Library TGF-beta/Smad Compound Library Epigenetics Compound Library Kinase Inhibitor Library